Fentanyl Transdermal System CII, 25mcg/h, packaged in a pouch, further packaged in 5-count carton...
FDA Drug Recall #D-0245-2025 - Class I, January 31, 2025
Recall Summary
| Recall Number | D-0245-2025 |
| Classification | Class I - Serious risk |
| Date Initiated | January 31, 2025 |
| Status | Ongoing |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Alvogen, Inc |
| Location | Morristown, NJ |
| Product Type | Drugs |
| Quantity | 112,128 cartons (5 pouches/carton) |
Product Description
Fentanyl Transdermal System CII, 25mcg/h, packaged in a pouch, further packaged in 5-count carton, Rx only, Distributed by: Alvogen, Inc., Pine Brook, NJ 07058, Manufactured by: Kindeva Drug Delivery L/P, Northridge, CA 91324, NDC 47781-424-47.
Reason for Recall
Defective delivery system - patches could be multi-stacked, adhered one on top of the other, in a single product pouch.
Distribution Pattern
USA Nationwide
Lot / Code Information
Lot #: 108319, Exp: 04/30/2027
Other Recalls from Alvogen, Inc
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0259-2026 | Class II | Levothyroxine Sodium Tablets, USP, Thyro-Tabs, ... | Dec 31, 2025 |
| D-0353-2023 | Class II | Levothyroxine Sodium Tablets, USP 112 mcg, 90 t... | Feb 6, 2023 |
| D-0649-2021 | Class II | Buprenorphine and Naloxone Sublingual Film 2mg/... | Feb 26, 2021 |
| D-1723-2019 | Class II | Macrobid Urinary Tract Anitbacterial, 100 mg, ... | Jul 24, 2019 |
| D-1722-2019 | Class II | Nitrofurantoin Monohydrate/Macrycrystals Capsul... | Jul 24, 2019 |
Frequently Asked Questions
Stop taking the medication and contact your pharmacist or doctor immediately. For Class I recalls, this is urgent. For Class II or III recalls, consult your doctor before stopping, abruptly discontinuing certain medications (blood pressure drugs, antidepressants, diabetes medications) can be more harmful than continuing while arranging a replacement. Check whether the recall applies to your specific lot number and expiration date. Return the product to your pharmacy and report any adverse effects to FDA MedWatch at 1-800-FDA-1088.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications, even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications, use a drug take-back program.